Treatment of Refractory Antibody-mediated Rejection with Bortezomib in a Kidney Transplant Recipient: A Case Report / 대한이식학회지
Ji-Yeon LEE; Jin-Young YOO; Soon-Hyo KWON; Jin-Seok JEON; Hyunjin NOH; Dong-Cheol HAN; Dan SONG; So-Young JIN.
The Journal of the Korean Society for Transplantation
; : 87-90, 2014.
Artículo
en Ko
| WPRIM | ID: wpr-95530
Antibody-mediated rejection (ABMR) is associated with poor renal allograft survival. It shows poor response to conventional treatment with plasmapheresis, rituximab, and intravenous immunoglobulin. Bortezomib, a proteasome inhibitor used for treatment of multiple myeloma, has recently been reported as a treatment alternative for recipient desensitization and ABMR. A 58-year-old man was diagnosed with mixed-type ABMR with donor specific antibodies and acute T cell-mediated rejection early after kidney transplantation. Conventional therapy was administered, including antithymocyte globulin, plasmapheresis, and rituximab; however, his condition was found to be refractory to these antihumoral therapies. Following administration of bortezomib, his serum creatinine level returned to baseline with stable graft function. His serum creatinine level remains stable at 1.3 mg/dL at 10 months posttransplantation. Bortezomib is effective for treatment of refractory ABMR following kidney transplantation.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados